Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080142 | 0.92 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL9208969 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL12020298 | 0.88 | ESR1 (0.58) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL25011313 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2916273 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL1686217 | 0.86 | ERCC5 (0.59) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL1694519 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL1739390 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL70968 | 0.86 | ERCC5 (0.58) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL3864104 | 0.85 | NPC1 (0.58) | ALDH1A1SMN1; SMN2RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-114057646-B | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-114057646-A | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2022-02-18 | — | — | CN | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0418845-B1 | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5134142-A | PYRAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-28 | — | — | US | disclosed |
| EP-0418845-A1 | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | ALDH1A1 139/4885SMN1; SMN2 3778/4885POLB 3329/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | ALDH1A1 4122/4885SMN1; SMN2 4321/4885POLB 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.